In our study, serum pre-treatment sPD-1 was detected only in the analysis limited to patients treated with NAs; NAs are administered to a large number of patients with chronic HBV infection, who may have a higher risk of HCC. The gene discussed is HOXD13; the disease is hepatocellular carcinoma.